Fertility and weight are more closely connected than many people realize, and for patients who are navigating both obesity and reproductive health concerns, the arrival of GLP-1 medications has raised a set of genuinely important questions. Can these medications affect fertility? Should they be used while trying to conceive? What does the research say, and what does it not yet know?
These are questions that deserve honest, evidence-based answers, delivered with the same compassion and clarity that should accompany every conversation about reproductive health. The science in this area is still developing, and part of being a trustworthy source of information is being transparent about where the evidence is strong, where it is preliminary, and where uncertainty remains.
How Obesity Affects Fertility
Before exploring what GLP-1 medications do to fertility, it is worth understanding what obesity itself does, because the two conversations are deeply intertwined and cannot be fully separated.
Obesity has well-documented effects on reproductive health in both women and men. In women, excess body fat disrupts the hormonal signaling that regulates the menstrual cycle and ovulation. Fat tissue is hormonally active and produces estrogen through a process involving an enzyme called aromatase, which converts androgens into estrogen. When excess fat tissue is present, this conversion produces higher levels of circulating estrogen than the reproductive system is designed to manage, which interferes with the precise hormonal feedback loops that govern ovulation.
The result is that women with obesity are significantly more likely to experience irregular or absent menstrual cycles, anovulation, which is the failure to release an egg during the menstrual cycle, and conditions like polycystic ovarian syndrome (PCOS), now known as polyendocrine metabolic ovarian syndrome (PMOS), that involve complex hormonal dysregulation with insulin resistance at its core. Fertility rates are lower in women with obesity, rates of miscarriage are higher, and outcomes in assisted reproduction such as IVF are less favorable compared to women at a lower body weight.
In men, obesity similarly disrupts hormonal balance by increasing estrogen relative to testosterone through the same aromatase mechanism. This shift reduces sperm quality, lowers testosterone levels, and contributes to reduced libido and erectile dysfunction in some cases. Research has shown that male obesity is associated with lower sperm concentration, reduced sperm motility, and higher rates of DNA fragmentation in sperm, all of which reduce the likelihood of successful conception.
Understanding this baseline is important because it establishes that treating obesity itself is a meaningful fertility intervention, and that any treatment that effectively reduces excess weight and improves metabolic health is likely to have positive downstream effects on reproductive function.
How GLP-1 Medications May Support Fertility
Given the negative effects of obesity on fertility and the ability of GLP-1 medications to address obesity and its metabolic consequences, there are several plausible mechanisms through which GLP-1 therapy may support fertility outcomes.
Improving Insulin Sensitivity and PCOS/PMOS
Polycystic ovarian syndrome (PCOS), now known as polyendocrine metabolic ovarian syndrome (PMOS), is one of the most common causes of female infertility and is deeply connected to insulin resistance. As discussed in earlier articles in this series, GLP-1 medications improve insulin sensitivity through multiple mechanisms, reducing fasting insulin levels, improving cellular response to insulin signaling, and lowering the chronic hyperinsulinemia that drives the hormonal dysregulation characteristic of PMOS.
In women with PMOS, reducing insulin resistance has been shown to lower androgen levels, regularize menstrual cycles, improve ovulation rates, and meaningfully improve fertility outcomes. Several studies have demonstrated that GLP-1 receptor agonists produce these effects in women with PMOS, both through their direct metabolic actions and through the weight loss they facilitate, which independently improves insulin sensitivity.
For women with PMOS who are struggling to conceive, GLP-1 therapy as part of a comprehensive fertility-supportive treatment plan represents a clinically logical approach that addresses the root metabolic cause of their hormonal disruption rather than simply managing its symptoms.
Restoring Hormonal Regulation Through Weight Loss
Beyond PMOS specifically, the weight loss produced by GLP-1 medications can restore more normal hormonal cycling in women with obesity-related menstrual irregularity. Studies on weight loss in women with obesity consistently show that even modest reductions in body weight of five to ten percent can meaningfully improve menstrual regularity, ovulation rates, and natural conception rates. GLP-1 medications that produce fifteen to twenty percent weight loss have the potential to produce even more significant hormonal normalization.
This mechanism is not unique to GLP-1 medications but applies to any effective weight loss intervention. What GLP-1 medications offer specifically is the ability to achieve meaningful weight loss in a medically supervised, non-surgical context for patients who have not been able to achieve it through lifestyle measures alone.
Reducing Inflammation
Chronic low-grade inflammation, which is closely associated with obesity and insulin resistance, is increasingly recognized as a contributor to reproductive dysfunction in both women and men. Inflammatory cytokines interfere with ovarian function, implantation, and early embryonic development. GLP-1 medications have demonstrated anti-inflammatory properties that extend beyond their weight loss effects, and reducing systemic inflammation may contribute to an improved reproductive environment independent of weight changes alone.
What the Current Evidence Shows
The direct evidence base for GLP-1 medications and fertility outcomes is still relatively limited and largely observational at this stage, which means conclusions should be drawn carefully and with appropriate acknowledgment of what is not yet known.
Studies examining GLP-1 medications in women with PCOS/PMOS have shown improvements in menstrual regularity, ovulation rates, and hormonal markers including reduced testosterone and improved insulin metrics. Case reports and small observational studies have documented pregnancies in women with obesity and infertility who conceived following GLP-1 therapy, including some who had not responded to other fertility treatments. Animal studies have suggested potential direct effects of GLP-1 receptor signaling on ovarian function and embryonic development, though translating findings from animal models to human reproductive medicine requires significant caution.
What is largely absent at this point is robust, randomized controlled trial data specifically examining GLP-1 medications as a fertility treatment and measuring pregnancy rates, live birth rates, and obstetric outcomes as primary endpoints. This kind of high-quality evidence is the standard to which fertility treatments are held, and the field is awaiting it. The absence of this data does not mean the medications are ineffective for fertility purposes. It means the evidence is not yet at the level of certainty that would support clear, guideline-level clinical recommendations.
The Critical Safety Question: GLP-1 Medications and Pregnancy
This is where the conversation becomes particularly important and requires complete clarity. GLP-1 medications are not approved for use during pregnancy, and current clinical guidance from the manufacturers and from major medical organizations is to discontinue these medications prior to attempting conception.
The primary concern is not that these medications are known to harm human pregnancies, because the evidence base in pregnant humans is extremely limited. The concern is that animal studies have shown adverse effects on fetal development at doses comparable to those used therapeutically in humans, and that in the absence of robust human safety data, the precautionary principle appropriately applies.
Animal studies with semaglutide and liraglutide have shown dose-dependent increases in fetal malformations and early pregnancy losses, though the doses used in some of these studies exceeded clinical doses and the relevance to human pregnancy is not fully established. Tirzepatide's animal reproductive toxicology data shows similar concerns. None of this constitutes proof of harm in human pregnancy, but it is sufficient to justify clear guidance against use during pregnancy until better safety data is available.
The current recommendation from manufacturers and from clinical guidelines is to discontinue GLP-1 medications at least two months before attempting to conceive. This timeline accounts for the elimination of the medication from the body and allows for the stabilization of weight and metabolic parameters before pregnancy begins. Some clinicians recommend a longer washout period of up to six months to ensure metabolic stability before conception, and individual clinical guidance may vary based on the specific medication and the patient's circumstances.
It is also worth noting that GLP-1 medications may improve fertility in ways that lead to unintended pregnancy in patients who were not expecting to be able to conceive. Women who have experienced infertility related to PMOS or obesity-related anovulation and who begin GLP-1 therapy may see menstrual cycles regularize and ovulatory function return, sometimes before they or their physician have fully considered the reproductive implications. This makes the conversation about contraception an essential part of initiating GLP-1 therapy in women of reproductive age, regardless of whether pregnancy is currently being attempted.
GLP-1 Medications and Oral Contraceptive Efficacy
One practical consideration that deserves specific attention is the potential interaction between GLP-1 medications and oral contraceptives. Because GLP-1 medications slow gastric emptying, they may affect the absorption of oral contraceptive pills, potentially reducing their efficacy.
The clinical significance of this interaction is not fully established, and the available data is limited. However, patients using oral contraceptives while on GLP-1 therapy should discuss this potential interaction with their prescribing physician and consider whether additional or alternative contraceptive methods are appropriate during treatment. This is a conversation that is easily overlooked in the clinical context of obesity management but has meaningful implications for patients who do not wish to conceive.
Bariatric Surgery and Fertility
Because many patients considering GLP-1 medications are also considering or have had bariatric surgery, it is worth addressing how surgery fits into the fertility picture, particularly given that both treatments work through some of the same hormonal pathways.
Bariatric surgery, particularly in women with obesity-related infertility and PMOS, has been associated with significant improvements in fertility outcomes. The hormonal normalization that follows substantial weight loss after surgery, including improved insulin sensitivity, regularized menstrual cycles, reduced androgen levels, and improved ovulatory function, produces fertility benefits that mirror and in many cases exceed those seen with GLP-1 medications, consistent with the greater degree of weight loss that surgery typically produces.
However, bariatric surgery creates its own set of reproductive considerations. The period of rapid weight loss following surgery is generally not considered an appropriate time to attempt pregnancy, because the caloric restriction and nutritional changes involved create a potentially compromised nutritional environment for fetal development. Most bariatric surgery programs recommend waiting a minimum of twelve to eighteen months after surgery before attempting conception, allowing weight to stabilize and nutritional status to normalize.
Women who become pregnant after bariatric surgery require careful nutritional monitoring throughout pregnancy, with particular attention to iron, folate, calcium, vitamin D, vitamin B12, and other nutrients that are at risk of deficiency in the post-surgical population and that are critical to fetal development.
For women of reproductive age who are considering both fertility and weight loss treatment, the timing and sequencing of these interventions requires a thoughtful, individualized conversation that accounts for their specific fertility situation, their weight loss needs, and their reproductive timeline.
What Patients Should Discuss With Their Care Team
For any patient at the intersection of GLP-1 therapy and fertility planning, several conversations with their care team are essential before, during, and after treatment.
Questions worth raising include whether GLP-1 therapy is appropriate as part of a fertility-supportive plan for a specific diagnosis such as PMOS or obesity-related anovulation, what the recommended washout period is before attempting conception given the specific medication being used, whether current contraceptive methods remain fully effective during GLP-1 therapy, what the plan is for nutritional and metabolic monitoring during the transition from GLP-1 therapy to attempting conception, and whether the patient's fertility situation warrants involvement of a reproductive endocrinologist alongside their obesity medicine or bariatric care.
This is a clinical picture that benefits enormously from coordinated care between the obesity medicine or bariatric physician and the reproductive medicine team. Patients navigating both weight and fertility concerns deserve specialists who communicate with each other and who approach the patient's goals as complementary rather than competing priorities.
An Evolving Area of Medicine
The relationship between GLP-1 medications and fertility sits at the intersection of two fields that are both advancing rapidly. Obesity medicine has been transformed by these medications in ways that continue to unfold, and reproductive medicine is beginning to grapple seriously with the metabolic dimensions of infertility that obesity creates. The convergence of these fields is producing new questions, new research, and new clinical possibilities that will continue to develop over the coming years.
What is already clear is that treating obesity effectively improves reproductive health in meaningful and documented ways, and that GLP-1 medications represent a powerful tool for achieving that treatment in appropriate patients. What requires continued caution is their use in the periconceptional period and during pregnancy, where the precautionary principle applies until the safety data in humans reaches a higher level of certainty.
Patients navigating these questions deserve honest, current, individualized guidance from physicians who understand both the promise and the limitations of what is known, and who take their reproductive goals as seriously as their metabolic ones.